Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12.
A candidate Lyme vaccine was administered to 20 adult volunteers following a 0, 1, 2 months vaccination schedule, with a booster at 12 months. An immune response, assessed as 'LA-2 equivalent' antibody titres using an inhibition ELISA, was induced in all vaccinees which persisted until the booster. Titres were increased 25-fold following the booster and persisted through month 24. There was a good correlation between 'LA-2 equivalent' antibody titres and a bactericidal assay (r2 = 0.86). Local symptoms were mild, resolving spontaneously within 72 h, with no reports of rash, arthralgia or other systemic symptoms. This Lyme vaccine was safe, well-tolerated and elicited an antibody response in all volunteers which persisted at least 12 months after the booster.
SmithKline Beecham Biologicals, Rixensart, Belgium.
C
C
Van Hoecke
D
D
Fu
D
D
De Grave
P
P
Voet
E
E
Lebacq
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D001770:Blood Bactericidal Activity; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D008074:Lipoproteins; D008297:Male; D008875:Middle Aged
D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein